This new report from the Publisher provides aprehensive analysis of the Middle East therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers.
The report provides test volume and sales forecasts by country and market segment for the following assays:
Amikacin, Apixaban, Argatroban, Betrixaban, Carbamazepine, Cyclosporin, Dabigatran, Digoxin, Edoxaban, Everolimus, Fluindione, Gentamicin, Levetiracetam, Lithium, Methotrexate, NAPA/Procainamide, Phenobarbital, Phenytoin, Quinidine, Rivaroxaban, Sirolimus, Tacrolimus, Theophylline, Tobramycin, Topirimate, Valproic Acid, Vaycin, and Warfarin.
During the next five years, the TDM market will undergo significant transformation. These changes will be caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying petition.
Some segments will start resemblingmodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others.
This unique market and technology assessment is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities and developed effective strategic responses. The study provides five-year forecasts for major TDM assays;pares features of leading analyzers; and profiles keypetitors.
The report provides test volume and sales forecasts by country and market segment for the following assays:
Amikacin, Apixaban, Argatroban, Betrixaban, Carbamazepine, Cyclosporin, Dabigatran, Digoxin, Edoxaban, Everolimus, Fluindione, Gentamicin, Levetiracetam, Lithium, Methotrexate, NAPA/Procainamide, Phenobarbital, Phenytoin, Quinidine, Rivaroxaban, Sirolimus, Tacrolimus, Theophylline, Tobramycin, Topirimate, Valproic Acid, Vaycin, and Warfarin.
During the next five years, the TDM market will undergo significant transformation. These changes will be caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying petition.
Some segments will start resemblingmodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others.
This unique market and technology assessment is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities and developed effective strategic responses. The study provides five-year forecasts for major TDM assays;pares features of leading analyzers; and profiles keypetitors.
